J
Julien Domont
Researcher at Institut Gustave Roussy
Publications - 113
Citations - 7193
Julien Domont is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: GiST & Soft tissue sarcoma. The author has an hindex of 37, co-authored 113 publications receiving 6024 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga,José Baselga,Ian Bradbury,Holger Eidtmann,Serena Di Cosimo,Serena Di Cosimo,Evandro de Azambuja,Claudia Aura,Henry L. Gomez,Phuong Dinh,Karine Fauria,Veerle Van Dooren,Gursel Aktan,Aron Goldhirsch,Tsai Wang Chang,Zsolt Horváth,Maria Antonia Coccia-Portugal,Julien Domont,Ling Min Tseng,Georg Kunz,Joohyuk Sohn,Vladimir Semiglazov,Guillermo Lerzo,Marketa Palacova,Volodymyr Probachai,Lajos Pusztai,Michael Untch,Richard D. Gelber,Martine Piccart-Gebhart +28 more
TL;DR: Dual inhibition of Her2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting, and the two anti-HER2 agents given together would be better than single-agent therapy.
Journal ArticleDOI
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick,Thierry Gorlia,Martin Bendszus,Martin J.B. Taphoorn,Felix Sahm,Inga Harting,Alba A. Brandes,Walter Taal,Julien Domont,Ahmed Idbaih,Mario Campone,Paul Clement,Roger Stupp,Michel Fabbro,Emilie Le Rhun,François Dubois,Michael Weller,Andreas von Deimling,Vassilis Golfinopoulos,Jacoline C. Bromberg,Michael Platten,Martin Klein,Martin J. van den Bent +22 more
TL;DR: Despite somewhat prolonged progression‐free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with LOMustine alone in patients with progressive glioblastoma.
Journal ArticleDOI
Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study
Thomas Bachelot,Gilles Romieu,Mario Campone,Véronique Diéras,Claire Cropet,Florence Dalenc,Marta Jimenez,Emilie Le Rhun,Jean-Yves Pierga,Anthony Gonçalves,Marianne Leheurteur,Julien Domont,Maya Gutierrez,Hervé Curé,Jean-Marc Ferrero,Catherine Labbe-Devilliers +15 more
TL;DR: The combination of lapatinib and capecitabine is active as first-line treatment of brain metastases from HER2-positive breast cancer and a phase 3 trial is warranted.
Journal ArticleDOI
Impact of EGFR expression on colorectal cancer patient prognosis and survival
J-P. Spano,Christine Lagorce,D. Atlan,Gérard Milano,Julien Domont,Robert Benamouzig,A. Attar,J. Benichou,Anne-Laure Martin,Jean-François Morère,Martine Raphael,Frédérique Penault-Llorca,J.-L. Breau,Remi Fagard,David Khayat,Philippe Wind +15 more
TL;DR: EGFR was overexpressed in this CRC patient population and was significantly associated with TNM (tumor-node-metastasis) stage T3, which suggests this expression-stage association may play a crucial role in a decision to initiate an adjuvant treatment.
Journal ArticleDOI
Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment
Marco Fiore,Françoise Rimareix,Luigi Mariani,Julien Domont,Paola Collini,Cécile Le Péchoux,Paolo G. Casali,Axel Le Cesne,Alessandro Gronchi,Sylvie Bonvalot +9 more
TL;DR: A conservative policy could be a safe approach to primary and recurrent DF, which could avoid unnecessary morbidity from surgery and/or radiation therapy, and a multidisciplinary, stepwise approach should be prospectively tested in DF.